- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- Betrixaban, Enoxaparin
- Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 7,513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 24
- States / cities
- Escondido, California • New Haven, Connecticut • Columbus, Georgia + 19 more
- Conditions
- Sleep Restriction
- Interventions
- Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Alopecia Areata
- Interventions
- Tralokinumab, Placebo
- Drug
- Lead sponsor
- Emma Guttman
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Asthma
- Interventions
- MEDI528 30 mg, MEDI528 100 mg, MEDI528 300 mg, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 24
- States / cities
- Pell City, Alabama • Los Angeles, California • Sacramento, California + 21 more
- Conditions
- Temporomandibular Disorders
- Interventions
- Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- RGLS8429, Placebo volume-matching RGLS8429 dose
- Drug
- Lead sponsor
- Regulus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Achondroplasia
- Interventions
- Navepegritide, Placebo for Navepegritide
- Drug
- Lead sponsor
- Ascendis Pharma A/S
- Industry
- Eligibility
- 0 Years to 2 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 72
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more
- Conditions
- Acromegaly
- Interventions
- IONIS-GHR-LRx, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 3 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 622 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 19
- States / cities
- Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Imsidolimab, Placebo
- Biological
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Northridge, California + 14 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Adalimumab, Placebo
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 76
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
- Conditions
- Safety Issues
- Interventions
- VIB9600, Placebos
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Psoriasis, Cardiovascular Disease
- Interventions
- Ustekinumab, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Teriparatide (FORTEO), Placebos
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Portland, Oregon • Houston, Texas
- Conditions
- Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
- Interventions
- taldefgrobep alfa, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more
- Conditions
- Giant Cell Arteritis
- Interventions
- Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
- Conditions
- Healthy
- Interventions
- PF-07314470, Placebo for PF-07314470
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- SAR156597, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, Gantenerumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 30
- States / cities
- Sun City, Arizona • Tucson, Arizona • Costa Mesa, California + 27 more
- Conditions
- Arterial Stiffening, Aging, Menopause
- Interventions
- GnRHant - Ganirelix acetate, Transdermal estradiol patch, Transdermal placebo patch
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Type 1 Diabetes (T1D)
- Interventions
- Golimumab, Placebo (matching golimumab)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 2 Years to 44 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Thyroid Eye Disease, TED
- Interventions
- MHB018A, MHB018A placebo
- Drug
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida